Somatic deletion of<i>KDM1A/LSD1</i>gene is associated to advanced colorectal cancer stages

Ramírez-Ramírez, Ruth; Gutiérrez-Angulo, Melva; Peregrina-Sandoval, Jorge; Moreno-Ortiz, José Miguel; Franco-Topete, Ramón Antonio; Cerda-Camacho, Felipe; Ayala-Madrigal, María de la Luz

doi:10.1136/jclinpath-2019-206128

Cited by 15 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…KDM1A was overexpressed in various malignant tumors, including cervical cancer ( 38 ), esophageal cancer ( 39 ), ovarian cancer ( 40 ), and GC ( 41 ). The elevated KDM1A level was also related to tumor stage, histological grade, and lymph node metastasis ( 42 ). Additionally, KDM1A is a regulator of embryonic stem cells and can affect the self-renewal and differentiation of human embryonic stem cells ( 43 ).…”

Section: Discussionmentioning

confidence: 99%

RETRACTED: OTUB2 Facilitates Tumorigenesis of Gastric Cancer Through Promoting KDM1A-Mediated Stem Cell-Like Properties

2021

View full text Add to dashboard Cite

Otubain 2 (OTUB2), a deubiquitinating enzyme, overexpression is considered to predict poor outcome in various cancers. However, the function and potential regulatory mechanisms of OTUB2 in gastric cancer (GC) progression remains unclear. To determine how OTUB2 participate in GC progression, the gain and loss of-function experiments were conducted in vivo and in vitro. We found that OTUB2 was upregulated in GC samples (n=140) and cells. Moreover, the overall, first progression and post progression survival rates of GC patients with high OTUB2 expression showed a poorer prognosis than that in those patients with low OTUB2 expression. Down-regulation of OTUB2 suppressed sphere formation and reduced expression of stem cell markers in GC cells. Furthermore, OTUB2-silenced GC cells also showed a decreased proliferation, invasion, migration, and in vivo tumorigenic ability. However, OTUB2 overexpression showed the opposite effects. Notably, we demonstrated that OTUB2 increased lysine-specific histone demethylase 1A (KDM1A) expression through deubiquitination. KDM1A, a demethylase known to promote demethylation of downstream genes, was identified to promote the maintenance of cancer stem cell characteristics. Moreover, the alterations caused by OTUB2 overexpression were partly inversed by KDM1A knockdown and in turn KDM1A overexpression reversed the changes induced by OTUB2 shRNA. Taken together, we demonstrate that OTUB2 may serve as a vital driver in GC tumorigenesis by enhancing KDM1A-mediated stem cell-like properties.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED: OTUB2 Facilitates Tumorigenesis of Gastric Cancer Through Promoting KDM1A-Mediated Stem Cell-Like Properties

2021

View full text Add to dashboard Cite

show abstract

“…Some of the 12 functional genes have been connected with COAD or other diseases according to the existing research. For example, TPM2 was reported to be in implicated in CRC [ 60 ]; STMN2 might be involved in beta-catenin/TCF-mediated carcinogenesis in human hepatoma cells [ 61 ]; CHMP4C was identified as a novel molecular target gene for ovarian cancer [ 62 ]; GRIA3 may act as a mediator of tumor progression in pancreatic cancer [ 63 ]; WDR1 was reported as a therapeutic target in lung cancer [ 64 ]; CPT2 was identified as a potential diagnostic biomarker of colon cancer [ 65 ]; Somatic deletion of KDM1A plays role in advanced colorectal cancer stages [ 66 ]; NFE2L1 , also called Nrf1, was found to be associated to high-risk diffuse large B cell lymphoma [ 67 ]; Gatza et al reported that TGFBR3 promotes colon cancer progression [ 68 ]; FGFR2 was shown to promote gastric cancer progression [ 69 ]. Therefore, the 12 functional genes probably play important roles in COAD and could be the potential prognosis biomarkers for COAD.…”

Section: Discussionmentioning

confidence: 99%

Network-based identification of biomarkers for colon adenocarcinoma

Wang

Yang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: As one of the most common cancers with high mortality in the world, we are still facing a huge challenge in the prevention and treatment of colon cancer. With the rapid development of high throughput technologies, new biomarkers identification for colon cancer has been confronted with the new opportunities and challenges. Methods: We firstly constructed functional networks for each sample of colon adenocarcinoma (COAD) by using a sample-specific network (SSN) method which can construct individual-specific networks based on gene expression profiles of a single sample. The functional genes and interactions were identified from the functional networks, respectively. Results: Classification and subtyping were used to test the function of the functional genes and interactions. The results of classification showed that the functional genes could be used as diagnostic biomarkers. The subtypes displayed different mechanisms, which were shown by the functional and pathway enrichment analysis for the representative genes of each subtype. Besides, subtype-specific molecular patterns were also detected, such as subtype-specific clinical and mutation features. Finally, 12 functional genes and 13 functional edges could serve as prognosis biomarkers since they were associated with the survival rate of COAD. Conclusions: In conclusion, the functional genes and interactions in the constructed functional network could be used as new biomarkers for COAD.

show abstract

“…These results shed light on the role of DACH1 and introduce a possible prognostic marker and therapeutic goal for CRC patients [ 127 ]. Furthermore, lysine-specific demethylase 1 (LSD1), a well-known chromatin-modifying enzyme, is overexpressed in CRC and associated with proliferation and migration mainly by transduction of the phosphoinositide 3-kinase (PI3K)/Akt axis [ 128 ]. In this regard, Miller et al.…”

Section: Crispr/cas9 In Cancersmentioning

confidence: 99%

CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool

et al. 2022

View full text Add to dashboard Cite

The progress of genetic engineering in the 1970s brought about a paradigm shift in genome editing technology. The clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) system is a flexible means to target and modify particular DNA sequences in the genome. Several applications of CRISPR/Cas9 are presently being studied in cancer biology and oncology to provide vigorous site-specific gene editing to enhance its biological and clinical uses. CRISPR's flexibility and ease of use have enabled the prompt achievement of almost any preferred alteration with greater efficiency and lower cost than preceding modalities. Also, CRISPR/Cas9 technology has recently been applied to improve the safety and efficacy of chimeric antigen receptor (CAR)-T cell therapies and defeat tumor cell resistance to conventional treatments such as chemotherapy and radiotherapy. The current review summarizes the application of CRISPR/Cas9 in cancer therapy. We also discuss the present obstacles and contemplate future possibilities in this context.

show abstract

Somatic deletion ofKDM1A/LSD1gene is associated to advanced colorectal cancer stages

Cited by 15 publications

References 39 publications

RETRACTED: OTUB2 Facilitates Tumorigenesis of Gastric Cancer Through Promoting KDM1A-Mediated Stem Cell-Like Properties

RETRACTED: OTUB2 Facilitates Tumorigenesis of Gastric Cancer Through Promoting KDM1A-Mediated Stem Cell-Like Properties

Network-based identification of biomarkers for colon adenocarcinoma

CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool

Contact Info

Product

Resources

About